Dr. Reddy’s settles patent suit with Celgene

 Dr. Reddy’s settles patent suit with Celgene

Dr. Reddy’s Laboratories Ltd. Has announced the settlement of its litigation with Celgene, a wholly-owned subsidiary of Bristol Myers Squibb, relating to patents for Revlimid(lenalidomide) capsules. In a settlement of

All outstanding claims in the litigation, Celgene has agreed to provide Dr.Reddy’swith a licence to sell volume-limited amounts of generic lenalidomidecapsulesin the US after March 2022 subject to regulatory approval. The agreed-upon percentages are cone dential,the Hyderabad-based company stated. Wellness business.” Remdesivir is an experimental antiviral drug developed by Gilead Sciences as a course of treatment for COVID-19. Gilead entered into anon-exclusive licensing agreement with Jubilant Life Sciences for distribution to127 countries. Following this, Jubilant Life Sciences through its subsidiary Jubilant Generics has entered an exclusive agreement with Saptagir Laboratories to manufacture remdesivir.

Dr. Reddy’s is also licensed to sell generic lenalidomide capsules in the US without volume limitation beginning On January 31, 2026. “We are pleased with the settlement agreement, and look forward to bringing a generic version of lenalidomide to market soon subject to regulatory approval for the benefit of patients,” said Mr. Marc Kikuchi, CEO, North America Generics, Dr. Reddy’s Laboratories.